Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13D/A 0001193125-21-046616 0001695076 XXXXXXXX LIVE 3 Common Stock, $0.00001 par value 02/05/2026 false 0001641281 097702203 Bolt Biotherapeutics, Inc. 900 Chesapeake Drive Redwood City CA 94063 Robert Hopfner (415) 697-1002 Pivotal bioVenture Partners Fund I UGP 501 2nd Street, Suite 200 San Francisco CA 94107 Louis Rambo (202) 416-6800 Proskauer Rose, LLP 1001 Pennsylvania Avenue NW, Suite 600 Washington DC 20004-2533 0001782539 N Nan Fung Group Holdings Limited b AF N D8 0 128119 0 128119 128119 N 6.7 CO Y NF Investment Holdings Limited b AF N D8 0 128119 0 128119 128119 N 6.7 CO 0001695076 N Pivotal bioVenture Partners Fund I, L.P. b WC N E9 0 78445 0 78445 78445 N 4.1 PN 0001752862 N Pivotal bioVenture Partners Fund I G.P., L.P. b AF N E9 0 78445 0 78445 78445 N 4.1 PN Y Pivotal bioVenture Partners Fund I U.G.P. Ltd. b AF N E9 0 78445 0 78445 78445 N 4.1 CO Y Pivotal Partners Ltd b AF N E9 0 78445 0 78445 78445 N 4.1 CO Y Pivotal Life Sciences Holdings Limited b AF N E9 0 78445 0 78445 78445 N 4.1 CO Y Nan Fung Life Sciences Holdings Limited b AF N D8 0 123119 0 123119 123119 N 6.4 CO Y Permwell Management Limited b WC N E9 0 5000 0 5000 5000 N 0.3 CO Y NFLS Beta Limited b WC N D8 0 44674 0 44674 44674 N 2.3 CO Y NFLS Platform Holdings Limited b WC N E9 0 44674 0 44674 44674 N 2.3 CO Common Stock, $0.00001 par value Bolt Biotherapeutics, Inc. 900 Chesapeake Drive Redwood City CA 94063 Items 5(a)-(c) of the Schedule 13D are amended and restated as follows: The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 1,919,441 outstanding shares of Common Stock, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2025. In addition, Mr. Kam Chung Leung directly owns 8,684 shares of Common Stock. The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference. Except as set forth on Schedule A, which is incorporated into this Item 5(c) by reference, no Reporting Person has effected any transaction in shares of Common Stock in the past sixty days. Nan Fung Group Holdings Limited /s/ Tang Chun Wai Nelson Tang Chun Wai Nelson, Director 02/17/2026 NF Investment Holdings Limited /s/ Tang Chun Wai Nelson Tang Chun Wai Nelson, Director 02/17/2026 Pivotal bioVenture Partners Fund I, L.P. By Pivotal bioVenture Partners Fund I G.P., L.P. its General Partner 02/17/2026 By Pivotal bioVenture Partners Fund I U.G.P., Ltd. its General Partner 02/17/2026 /s/ Robert Hopfner Robert Hopfner, Authorized Signatory 02/17/2026 Pivotal bioVenture Partners Fund I G.P., L.P. By Pivotal bioVenture Partners Fund I U.G.P., Ltd. its General Partner 02/17/2026 /s/ Robert Hopfner Robert Hopfner, Authorized Signatory 02/17/2026 Pivotal bioVenture Partners Fund I U.G.P. Ltd. /s/ Robert Hopfner Robert Hopfner, Authorized Signatory 02/17/2026 Pivotal Partners Ltd /s/ Sun Xintong Sun Xintong, Director 02/17/2026 Pivotal Life Sciences Holdings Limited /s/ Sun Xintong Sun Xintong, Director 02/17/2026 Nan Fung Life Sciences Holdings Limited /s/ Sun Xintong Sun Xintong, Director 02/17/2026 Permwell Management Limited /s/ Tang Chun Wai Nelson Tang Chun Wai Nelson, Director 02/17/2026 NFLS Beta Limited /s/ Sun Xintong Sun Xintong, Director 02/17/2026 NFLS Platform Holdings Limited /s/ Sun Xintong Sun Xintong, Director 02/17/2026